Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
It's worth the wait
#Obesity #EASO #NatureMedicine #Tirzepatide #Semaglutide #MetabolicHealth #PersonalizedMedicine To view or add a comment, sign in Eli Lilly and Companys three strategies to expand obesity market(TAM) The global obesity drug market is forecast to grow from US$11.6bn in 2022, to US$68.9bn in 2025, and to US$150.6bn in 2030
In contract negotiations, a PBM can point to an MFP of $200/month for Drug X and argue that its current net price of $350/month (after rebates) is indefensible relative to what Medicare is paying
novel peptides like retatrutide, GLP-3) is under development ( [35] )
US$ 27.17
US$ 20.03
US$ 28.76
US$ 28.55
